NEW YORK (GenomeWeb News) – Nicox, a company specializing in ophthalmic therapies and diagnostics, will market Sequenom's RetnaGene AMD test in North America, the partners said today.

Under the terms of the agreement, Nicox has gained exclusive North American promotional rights to Sequenom Laboratories' RetnaGene laboratory-developed test, which evaluates a patient's risk of AMD disease progression within 2, 5 and 10 years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.